Blog

- April 24, 2026

CGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant ‘EASYMADE TI’

SEOUL, South Korea, April 24, 2026 /PRNewswire/ — CGBIO (CEO: Hyunseung Yu) announced that its patient-specific titanium implant, EASYMADE TI, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on April 9. The FDA 510(k) pathway is a premarket clearance process that demonstrates substantial equivalence to a legally marketed predicate device, allowing commercialization in the United States.

Read More »